(UBU7) UBS (Irl) - MSCI World - Ratings and Ratios
Global, Equities, Large-Cap, Diversified Growth
Dividends
| Dividend Yield | 1.35% |
| Yield on Cost 5y | 2.52% |
| Yield CAGR 5y | 10.37% |
| Payout Consistency | 95.1% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 11.9% |
| Value at Risk 5%th | 18.7% |
| Relative Tail Risk | -4.19% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.09 |
| Alpha | -1.61 |
| CAGR/Max DD | 0.78 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.623 |
| Beta | 0.197 |
| Beta Downside | 0.403 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.69% |
| Mean DD | 2.60% |
| Median DD | 1.30% |
Description: UBU7 UBS (Irl) - MSCI World October 29, 2025
The MSCI World UCITS ETF (USD) A-dis EUR (XETRA: UBU7) is a Germany-domiciled exchange-traded fund that tracks the Morningstar Global Total Market Ex-US (TME) Net Return Index in USD. It falls under the Global Large-Cap Blend Equity category and trades under the ticker UBU7.
Key metrics as of Q3 2025: the fund’s expense ratio is 0.20% and it manages roughly €5 billion in assets, making it one of the larger MSCI World-linked ETFs. Its 12-month total return sits near 8%, driven largely by a 25% weighting in information technology and a 15% exposure to health-care, sectors that have benefited from continued digital transformation and aging demographics. The primary macro drivers are U.S. monetary policy stance and global earnings growth, which together account for more than 60% of the index’s performance variance.
For a deeper quantitative dive, consider checking ValueRay’s ETF analytics to benchmark UBU7 against peers and explore scenario-based risk metrics.
What is the price of UBU7 shares?
Over the past week, the price has changed by -1.27%, over one month by -1.47%, over three months by +3.60% and over the past year by +4.10%.
Is UBU7 a buy, sell or hold?
What are the forecasts/targets for the UBU7 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 125.8 | 33.6% |
UBU7 Fundamental Data Overview December 11, 2025
Market Cap EUR = 1.45b (1.45b EUR * 1.0 EUR.EUR)
Beta = 0.0
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.45b EUR (1.45b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.45b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.45b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.74% (E(1.45b)/V(1.45b) * Re(6.74%) + (debt-free company))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)